Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.

"Declarations Ethics approval and consent to participateNothing to declare. Consent for publicationNothing to declare. Competing interestsH.-J.W. is founder and shareholder of Scintomics GmbH, Munich, Germany. A patent application on CCK-2R-targeted compounds with N.H., C.L., H.-J.W., and T.G. as inventors has been filed. No other potential conflicts of interest relevant to this article exist. Competing interests H.-J.W. is founder and shareholder of Scintomics GmbH, Munich, Germany. A patent application on CCK-2R-targeted compounds with N.H., C.L., H.-J.W., and T.G. as inventors has been filed. No other potential conflicts of interest relevant to this article exist."

"Funding Open Access funding enabled and organized by Projekt DEAL. This study has been funded by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation—461577150)."